Store

Home | Store | Cell and Gene Therapy Market and Deals Analysis, 2023

Cell and Gene Therapy Market and Deals Analysis, 2023

Publication Date: May 22, 2023

LICENSE

Clear

SKU: 23-022

Tags: CAR-T Cell Therapy, Cell and Gene Therapy, Life Science, Oncology and Cancer

Pages: 260

SKU: 23-022

Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals tracks deal-making and market opportunities in cell and gene therapy, providing specific details of 1000+ deals from 2022-2023. With a staggering $40 billion in CGT deals in 2022 alone, understanding the market dynamics and key players is essential for companies entering or already operating in this space.

Key Features:

In-depth analysis of 1000+ Cell and Gene Therapy Deals from 2022-2023
Overview of venture capital/private funding round amounts, by quarter
Detailed breakdown of deal types, including Technology/Research/Strategic Collaboration, Venture Capital/Private Investment, Acquisition, Merger, Strategic Investment, and more
Identification of the most active deal-making companies and their involvement in various types of deals
Regional breakdown of deal-making activities in North America, Europe, APAC, and Rest of World

Market Insights:

The report provides insights into the trends shaping the cell and gene therapy market, including estimated market forecasts for cell and gene therapies by type (Gene Therapy, Cell Therapy), by region (North America, EU, APAC, Other), and by disease category. With over 1,500 companies involved in the industry, this report offers a comprehensive view of the competitive landscape and future growth opportunities.

Why Choose Kalorama’s Report:

Kalorama’s report offers unparalleled insights into the cell and gene therapy deal-making landscape, providing valuable information for companies seeking to capitalize on the market’s rapid growth. With detailed analysis of deal trends, funding amounts, and regional activities, this report is a must-have resource for companies looking to navigate the complex world of cell and gene therapy deal-making.

Conclusion:

As the cell and gene therapy market continues to evolve, understanding the deal-making landscape is crucial for identifying opportunities and staying competitive. Kalorama’s report provides a comprehensive overview of the current market dynamics, making it an essential resource for companies looking to succeed in this rapidly growing industry.

Table: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q1 2023($M) (%)

Region	Q1 ’21	Q2	Q3	Q4	Q1 ’22	Q2	Q3	Q4	Q1 ’23	Overall	Share
N. America	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	XX%
Europe	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	XX%
APAC	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	XX%
ROW	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	XX%
Total	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	XX%
# disclosing $	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	XX%
avg round	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	$XX Million	XX%

Source: Kalorama Information

For further details and to purchase directly, please contact us.

Chapter 1: Executive Summary

Introduction

$40.2 Billion in Funding During 2022

Figure 1-1: Total Deals per Month, April 2021-March 2023 (Total count)
Figure 1-2: Total Deals per Month by Type, Apr 2021-Mar 2023 [VC/ Private, IPO/FPO/SPAC; and All Other Deals] (Total count)

Quarterly Funding Amounts

Table 1-1: Total Quarterly Funding, by Type, Q1 2021-Q4 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Table 1-2: Total Quarterly Funding, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2023 ($M)
Figure 1-4: Total Quarterly Funding, by Type, Q1 2021-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)

Quarterly Funding Category Shares, Q1 2021 Through Q1 2023

Table 1-3: Total Quarterly Funding Share, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Table 1-4: Total Quarterly Funding Share, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-5: Q1 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-6: Q2 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-7: Q3 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-8: Q4 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
Figure 1-9: Q1 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)

Quarterly Deal Counts by Category, Q1 2021 – Q1 2023

Table 1-5: Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
Table 1-6: Quarterly Count of Deals, by Quarter Q1 2022-Q1 2023, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)

Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy

Figure 1-10: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)

A Look at Less Frequent CGT Deal Types

Figure 1-11: Lower Frequency Deal Types, by Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
Figure 1-12: Merger/ Acquisition Amount, by Quarter [Q1 2021 – Q1 2023] ($M)
Figure 1-13: Venture Capital/Private Funding Round Amount, by Quarter [January 2021-January 2022] ($M)
Figure 1-14: IPO/FPO Amount, by Quarter [Q1 2021-Q1 2023] ($M)
Figure 1-15: SPAC Portion Amount, by Year and Q1 2023 ($M)

Synopsis of Most Active Deal-Making Companies

Table 1-7: Most Active Companies’ Deal-Making Rankings, by Category, 2021-Q1 2023 (Rank)
Table 1-8: Most Active Companies in Overall Deals, Collaborations
Figure 1-16: Most Active Companies in Overall Deals, Collaborations

Chapter 2: Venture Capital & Private Funding

VC/Private Funding in Flux

Figure 2-1: Total Number of VC/ Private Funding Deals by Month, January 2021-March 2023 (Total count)
Figure 2-2: Average VC/ Private Funding Round Amount, By Quarter Q1 2021-Q1 2023 ($M)
Table 2-1: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q1 2023, [North America, Europe, APAC, Rest of World] ($M) (%)
Figure 2-3: Quarterly Venture Capital/Private Total Funding, Q1 2021- Q1 2023, by Region [North America, Europe, APAC, Rest of World] ($M)
Table 2-2: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q1 2023, [North America, Europe, APAC, Rest of World] (%)
Figure 2-4: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021 Q1 2023, [North America, Europe, APAC, Rest of World] (%)
Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter [Q1 2021-Q1 2023] ($M)
Table 2-3: Venture Capital/Private Fundraising Deals, Q1 2023
Table 2-4: Venture Capital/Private Fundraising Deals, Q4 2022
Table 2-5: Venture Capital/Private, Q3 2022
Table 2-6: Venture Capital/Private Fundraising Deals, Q2 2022
Table 2-7: Venture Capital/Private Fundraising Deals, Q1 2022

Chapter 3: Strategic Investments

Strategic Investments in Cell and Gene Therapy

Figure 3-1: Total Number of Strategic Investments, By Quarter [Q1 2021-Q1 2023] (Total count)
Figure 3-2: Average Strategic Investment Amount, By Quarter [Q1 2021-Q1 2023] ($M)
Figure 3-3: Total Strategic Investments, By Quarter [Q1 2021-Q1 2023] ($M)
Table 3-1: Strategic Investment Total Amounts, Counts, and Averages, by Quarter, Q1 2021 Q1 2023, ($M)
Table 3-2: Strategic Investments, January 2021-April 2023

Most Active Companies

Table 3-3: Most Active in Acquisition/Merger/ Strategic Investment
Figure 3-4: Most Active in Acquisition/Merger/ Strategic Investment

Chapter 4: IPOs, FPOs, & SPACs

North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs

Figure 4-1: Total Number of IPOs/ FPOs, By Month [Jan 2021-Mar 2023] (Total count)
Figure 4-2: Average IPO/ FPO Proceeds, By Quarter [Q1 2021-Q1 2023] ($M)
Table 4-1: Quarterly IPO/ FPO Total Funding, Q1 2021 Q1 2023, by Region [North America, Europe, APAC] ($M)
Figure 4-3: Total IPO/ FPO Funding, By Quarter, by Region [Q1 2021-Q1 2023] ($M)
Table 4-2: Regional IPO/ FPO Funding Shares, by Quarter, Q1 2021 Q1 2023, [North America, Europe, APAC] (%)
Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021 Q1 2023 [North America, APAC, and Europe) (%)
Figure 4-5: IPO/FPO Amounts, By Quarter [Q1 2021-Q1 2023] ($M)
Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q1 2023 ($M)
Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q1 2023 ($M)
Table 4-4: IPO/FPO Deals, Q1 2023
Table 4-5: IPO/FPO Deals, Q4 2022
Table 4-6: IPO/FPO Deals, Q3 2022
Table 4-7: IPO/FPO Deals, Q2 2022
Table 4-8: IPO/FPO Deals, Q1 2022
Table 4-9: SPAC Portion, January 2021-Mar 2023 ($M)
Figure 4-7: SPAC Portion Amount, by Year, ’21, ’22, Q1 2023 ($M)

Chapter 5: Mergers & Acquisitions (M&A)

Growing Numbers of M&A, Despite Lower Average Value

Figure 5-1: Total Number of Mergers and Acquisitions, By Month [Jan 2021-Mar 2023] (Total Count)
Figure 5-2: Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q1 2023 ($M) (Total count)
Figure 5-3: Merger/ Acquisition Transactions Global Total, By Quarter [Q1 2022- Q1 2023] ($M)
Figure 5-4: Merger/ Acquisition Amounts, by Quarter [Q1 2021- Q1 2023] ($M)
Table 5-2: Mergers and Acquisitions Announcements, Q1 2023 ($M)
Table 5-3: Mergers and Acquisitions, Q4 2022 ($M)
Table 5-4: Mergers and Acquisitions, Q3 2022 ($M)
Table 5-5: Mergers and Acquisitions, Q2 2022 ($M)
Table 5-6: Mergers and Acquisitions, Q1 2022 ($M)

Most Active Companies

Table 5-7: Most Active in Acquisition/Merger/Strategic Investment
Figure 5-5: Most Active in Acquisition/Merger/ Strategic Investment

Chapter 6: Technology/Research/Strategic Collaborations

CGT Market Sees a Broad Variety of Collaborations

Figure 6-1: Total Number of Tech/ Research/ Strategic Collaborations, By Month [Jan 2021-Mar 2023] (Total count)
Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
Table 6-1: Collaboration Upfront and Future/ Milestone Payments, Counts, Averages, Q1 2021-Q1 2023 ($M) (Total count)
Figure 6-3: Average Collaboration Upfront Payment, By Quarter [Q1 2021-Q1 2023] ($M)
Figure 6-4: Total Collaboration Upfront Payments, By Quarter [Q1 2021-Q1 2023] ($M)
Figure 6-5: Average Collaboration Future/ Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
Figure 6-6: Total Collaboration Future/ Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
Table 6-2: Technology/Research/Strategic Collaboration Deals, January 2022–April 2023

Most Active Companies

Table 6-3: Most Active in Research/Strategic Collaborations
Figure 6-7: Most Active in Research/Strategic Collaborations

Chapter 7: Licensing

Stable Levels of Licensing in the Cell and Gene Therapy Market

Figure 7-1: Total Number of Licensing Deals, By Month [Jan 2021-Mar 2023] (Total count)
Table 7-1: Licensing Deals, January 2022-April 2023

Most Active Companies

Table 7-2: Most Active Companies in Licensing Deals
Figure 7-2: Most Active Companies in Licensing Deals

Chapter 8: Manufacturing and Supply Chain

Major Growth in Manufacturing and Supply Chain Management Activity in CGT

Figure 8-1: Total Number of Supply/ Manufacturing Deals, By Month [Jan 2021-Mar 2023] (Total count)
Table 8-1: Manufacturing and Supply Chain Deals, January 2022-March 2023

Most Active Companies

Table 8-2: Most Active Companies in Manufacturing/Supply Deals
Figure 8-2: Most Active Companies in Manufacturing/Supply Deals

Chapter 9: Public Outreach, Education, & Philanthropy

CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy

Figure 9-1: Total Number of Outreach/ Philanthropy/ Education Deals, By Month [Jan 2021-Mar 2023] (Total count)
Table 9-1: Outreach, Education, & Philanthropy Deals, January 2022-Apr 2023

Chapter 10: Distribution & Co-Marketing

A Look at CGT Distribution and Co-Marketing Deals

Figure 10-1: Total Number of Distribution/ Co-Marketing Deals, by Month [Jan 2021-Mar 2023] (Total count)
Table 10-1: Distribution & Co-Marketing Deals, January 2022-Mar 2023

Most Active Companies

Table 10-2: Most Active Companies in Distribution/Co-Marketing Deals
Figure 10-2: Most Active Companies in Distribution/Co-Marketing Deals

Chapter 11: Other – JV, Restructuring, Termination, Spinoffs

A Look at Other Types of Deals Impacting Cell and Gene Therapy

Figure 11-1: Total Number of JV, Restructuring, Termination, By Month [Jan 2021-Mar 2023] (Total count)
Table 11-1: Restructuring, JV, Termination, Spinoffs, January 2022-April 2023

Chapter 12: Other – New Facilities, Expansion; Real Estate

Expansion, New Facilities and Related Announcements

Table 12-1: New Facilities, Expansion; Real Estate Deals, January 2022-April 2023

Appendix: Cell and Gene Therapy Market Assessment

Market Outlook, 2022-2032

Table A-1: Cell and Gene Therapy Market Revenues by Product Type, 2022 and Projected 2027 and 2032 ($ millions)
Figure A-1: Cell and Gene Therapy Market Revenue Share, by Product Type [Cardiovascular-Blood, Dermatological, Musculoskeletal, Neurology, Oncology, Ophthalmic, Other Conditions] (%)

Regional Market

Table A-2: Cell and Gene Therapy Market by Country/Region [Europe, United States, Other Countries], 2022 Projected 2027 and 2032 ($ millions)

Products on the Market

Table A-3: Major Cell and Gene Therapy Product Approvals, FDA

Top Companies in Cell and Gene Therapy

Figure A-2: Leading Companies in Cell and Gene Therapy, By Company [Amylan, Bristol Myers, Dendreon, Gilead, Novartis, Smith and Nephew, Others]

Related products

The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition

April 23, 2024

Explore the latest trends and forecasts in the point-of-care (POC) diagnostic tests market with Kalorama Information’s The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11^th Edition. Discover the key growth areas and technological advancements shaping the future of POC diagnostics.

Lab-based analyzers in hospitals and reference labs are the cornerstone of revenues in the in…

$7,000.00 – $10,000.00

In Vitro Diagnostic (IVD) Trends and Market Update: March 2024

March 26, 2024

Explore the latest trends and developments in the in vitro diagnostic (IVD) market with Kalorama Information’s comprehensive report, In Vitro Diagnostic (IVD) Trends and Market Update: March 2024. Gain insights into key growth segments, industry trends, and emerging technologies shaping the future of IVD.

The report offers updated data analysis based on Kalorama Information’s annual…

$5,000.00 – $7,875.00

The World Market for Veterinary Diagnostics, 7th Edition

January 22, 2024

Unlock the potential of the veterinary diagnostics market with Kalorama Information’s comprehensive report, The World Market for Veterinary Diagnostics, 7th Edition, which dives deep into the world of animal healthcare diagnostics. From disease identification to monitoring, veterinarians rely on a variety of tests for accurate diagnoses and effective treatment plans. Our report provides a detailed…

$5,000.00 – $7,875.00

At-Home Diagnostic Testing Markets and Trends, 2023

Kalorama Information’s report, At-Home Diagnostic Testing Markets and Trends (COVID-19, FOB, Glucose, HIV, and Other Tests), 2023, delves into the expanding world of at-home and home collection tests. The at-home in vitro diagnostic (IVD) testing market comprises tests that can be purchased over the counter or online, where patients collect specimens and receive results within…

$4,000.00 – $6,000.00

Cell and Gene Therapy Deals Analysis, 2021-2024

Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…

$6,300.00 – $9,450.00

The World Market for Vaccines, 2024

Vaccines are a cornerstone of preventive medicine, offering long-term or permanent immunity against diseases. They have been instrumental in near-eliminating many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century. Kalorama Information’s latest report, The World Market for Vaccines, 2024, provides a comprehensive analysis of adult…

$5,000.00 – $7,875.00

Store

Cell and Gene Therapy Market and Deals Analysis, 2023

Table of Contents

Chapter 1: Executive Summary

Introduction

$40.2 Billion in Funding During 2022

Quarterly Funding Amounts

Quarterly Funding Category Shares, Q1 2021 Through Q1 2023

Synopsis of Most Active Deal-Making Companies

Chapter 2: Venture Capital & Private Funding

VC/Private Funding in Flux

Chapter 3: Strategic Investments

Strategic Investments in Cell and Gene Therapy

Most Active Companies

Chapter 4: IPOs, FPOs, & SPACs

North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs

Chapter 5: Mergers & Acquisitions (M&A)

Growing Numbers of M&A, Despite Lower Average Value

Most Active Companies

Chapter 6: Technology/Research/Strategic Collaborations

CGT Market Sees a Broad Variety of Collaborations

Most Active Companies

Chapter 7: Licensing

Stable Levels of Licensing in the Cell and Gene Therapy Market

Most Active Companies

Chapter 8: Manufacturing and Supply Chain

Major Growth in Manufacturing and Supply Chain Management Activity in CGT

Most Active Companies

Chapter 9: Public Outreach, Education, & Philanthropy

CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy

Chapter 10: Distribution & Co-Marketing

A Look at CGT Distribution and Co-Marketing Deals

Most Active Companies

Chapter 11: Other – JV, Restructuring, Termination, Spinoffs

A Look at Other Types of Deals Impacting Cell and Gene Therapy

Chapter 12: Other – New Facilities, Expansion; Real Estate

Expansion, New Facilities and Related Announcements

Appendix: Cell and Gene Therapy Market Assessment

Market Outlook, 2022-2032

Regional Market

Products on the Market

Top Companies in Cell and Gene Therapy

all market reports

Related products

The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 11th Edition

In Vitro Diagnostic (IVD) Trends and Market Update: March 2024

The World Market for Veterinary Diagnostics, 7th Edition

At-Home Diagnostic Testing Markets and Trends, 2023

Cell and Gene Therapy Deals Analysis, 2021-2024

The World Market for Vaccines, 2024

Market Outlook, 2022-2032

Regional Market

Products on the Market

Top Companies in Cell and Gene Therapy